J&J’s Rybrevant Faspro wins FDA priority review for advanced head and neck cancer treatment

Reuters2026/07/30 12:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Johnson & Johnson won FDA Priority Review for RYBREVANT FASPRO as a potential first-in-class subcutaneous EGFR/MET therapy in advanced head and neck cancer.
The sBLA targets adults with recurrent or metastatic HNSCC whose disease progressed on platinum chemotherapy and PD-1/PD-L1 treatment; FDA decision expected in about six months.
OrigAMI-4 data showed a 42% overall response rate for monotherapy, with more than one-third of responders achieving complete response.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607300830PR_NEWS_USPR_____NY11124) on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

J&J’s Rybrevant Faspro wins FDA priority review for advanced head and neck cancer treatment

You may also like

Crypto prices